{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:51Z","timestamp":1791407031469,"version":"4.3.3"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T00:00:00Z","timestamp":1675728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Breakpoint cluster region-Abelson gene (BCR-ABL) tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic myeloid leukemia (CML). However, concern has arisen about the cardiac safety profile of these drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aims to compare long-term risks of adverse cardiovascular and cerebrovascular events (ACE), heart failure or left ventricular ejection fraction (LVEF) &amp;lt; 50%, and venous thromboembolic events (VTE) in patients with CML treated with BCR-ABL TKIs, using data from a large multinational network.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients aged \u2265 18 years with CML treated with imatinib, dasatinib, or nilotinib without prior cardiovascular or cerebrovascular disease were included. We used propensity score matching to balance the cohorts. The 5-year cumulative incidences and hazard ratios were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 3,722 patients with CML under treatment with imatinib (<jats:italic>n<\/jats:italic> = 1,906), dasatinib (<jats:italic>n<\/jats:italic> = 1,269), and nilotinib (<jats:italic>n<\/jats:italic> = 547). Patients with imatinib compared to dasatinib showed a higher hazard ratio (HR) for ACE (HR 2,13, 95% CI 1.15\u20133.94, <jats:italic>p<\/jats:italic> = 0.016). Patients with imatinib presented a lower HR than nilotinib for ACE (HR 0.50, 95% CI 0.30\u20130.83, <jats:italic>p<\/jats:italic> = 0.0074). In relation to heart failure or LVEF &amp;lt; 50%, patients with imatinib had a higher HR than dasatinib (HR 9.41, 95% CI 1.22\u201372.17, <jats:italic>p<\/jats:italic> = 0.03), but no significant difference was observed between imatinib and nilotinib (HR 0.48, 95% CI 0.215\u20131.01, <jats:italic>p<\/jats:italic> = 0.064).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this retrospective study with a large number of patients with CML, those treated with nilotinib had a higher 5-year ratio of ACE, while patients with dasatinib showed a lower ratio than patients with imatinib. The ratio of heart failure was higher in patients with imatinib than in patients with dasatinib, but not when compared to nilotinib.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.888366","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T04:55:59Z","timestamp":1675745759000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Five-year cardiovascular outcomes in patients with chronic myeloid leukemia treated with imatinib, dasatinib, or nilotinib: A cohort study using data from a large multinational collaborative network"],"prefix":"10.3389","volume":"10","author":[{"given":"Rafael Amorim Belo","family":"Nunes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Precil Diego Miranda de Menezes","family":"Neves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro Menezes Alves","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bachour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo Jos\u00e9 de Carvalho","family":"Cantarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Bernardes de Figueiredo","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Avezum Jr.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,7]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2013a new oral targeted therapy.","volume":"346","author":"Wood","year":"2002","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6616265","article-title":"Assessment and management of cardiotoxicity in hematologic malignancies.","volume":"2021","author":"Bojan","year":"2021","journal-title":"Dis Markers."},{"key":"B4","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy.","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood."},{"key":"B5","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3892\/mco.2016.800","article-title":"Cardiotoxicity associated with targeted cancer therapies.","volume":"4","author":"Chen","year":"2016","journal-title":"Mol Clin Oncol."},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1038\/nm0107-13a","article-title":"In reply to \u2018Cardiotoxicity of the cancer therapeutic agent imatinib mesylate\u2019.","volume":"13","author":"Hatfield","year":"2007","journal-title":"Nat Med."},{"key":"B7","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib.","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial.","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis.","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia."},{"key":"B11","doi-asserted-by":"publisher","first-page":"6227","DOI":"10.2147\/OTT.S170138","article-title":"Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities.","volume":"11","author":"Chaar","year":"2018","journal-title":"Onco Targets Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag."},{"key":"B13","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/S2215-0366(20)30462-4","article-title":"Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62?354 COVID-19 cases in the USA.","volume":"8","author":"Taquet","year":"2021","journal-title":"Lancet Psychiatry."},{"key":"B14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care.","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijcard.2019.10.036","article-title":"Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.","volume":"301","author":"Caocci","year":"2020","journal-title":"Int J Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00277-017-3012-z","article-title":"Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios.","volume":"96","author":"Saglio","year":"2017","journal-title":"Ann Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1038\/leu.2017.245","article-title":"Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.","volume":"31","author":"Hadzijusufovic","year":"2017","journal-title":"Leukemia."},{"key":"B19","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3109\/10428194.2014.994205","article-title":"Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment.","volume":"56","author":"Gora-Tybor","year":"2015","journal-title":"Leuk Lymphoma."},{"key":"B20","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.","volume":"12","author":"Kerkel","year":"2006","journal-title":"Nat Med."},{"key":"B21","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"key":"B22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/MCP.0b013e328338c486","article-title":"Pleural effusions due to dasatinib.","volume":"16","author":"Brixey","year":"2010","journal-title":"Curr Opin Pulm Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural effusion in dasatinib-treated patients with chronic myeloid leukemia in chronic phase: identification and management.","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"B24","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study.","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/01621459.2016.1260466","article-title":"Balancing covariates via propensity score weighting.","volume":"113","author":"Li","year":"2018","journal-title":"J Am Stat Assoc."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.888366\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T04:56:07Z","timestamp":1675745767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.888366\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,7]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2023.888366"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.888366","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,7]]},"article-number":"888366"}}